September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Expression of PD-L1 and PD-1 in conjunctival melanoma
Author Affiliations & Notes
  • Jinfeng Cao
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Kate Richards
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Ekaterina S. Jordanova
    Pathology, Leiden University Medical Center, Leiden, Netherlands
    Gynecology, VU University Medical Center, Amsterdam, Netherlands
  • Marina Marinkovic
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Daan Hurkmans
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Sjoerd G. van Duinen
    Pathology, Leiden University Medical Center, Leiden, Netherlands
  • Pieter A. van der Velden
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Martine J Jager
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Footnotes
    Commercial Relationships   Jinfeng Cao, None; Kate Richards, None; Ekaterina Jordanova, None; Marina Marinkovic, None; Daan Hurkmans, None; Sjoerd G. Duinen, None; Pieter van der Velden, None; Martine Jager, None
  • Footnotes
    Support  China Scholarship Council
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2404. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jinfeng Cao, Kate Richards, Ekaterina S. Jordanova, Marina Marinkovic, Daan Hurkmans, Sjoerd G. van Duinen, Pieter A. van der Velden, Martine J Jager; Expression of PD-L1 and PD-1 in conjunctival melanoma. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2404.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : Current therapies of conjunctival melanoma (CM) include surgical excision combined with adjuvant cryotherapy, brachytherapy, and/or topical chemotherapy. However, therapeutic strategies with regard to metastases are often ineffective. As blocking the interaction between the programmed cell death (PD)-1 protein and its ligand, PD-L1, has been reported to have significant antitumor effects in other malignancies, we studied whether conjunctival melanoma express PD-L1 and PD-1 in vivo and in vitro.

Methods : 30 conjunctival malignant lesions obtained from 27 patients were collected. The presence of PD-L1 and PD-1 was assessed by immunofluorescence. Real-time qRT-PCR was performed to detect the gene expression of PD-L1 and PD-1 in three CM cell lines (CRMM1, CRMM2 and CM2005.1). Flow cytometry was used to analyse the cell surface expression of PD-L1 and PD-1 of CM cell lines.

Results : 19% of CM cases showed PD-L1 positivity in the tumor cells, while 57% of cases expressed PD-L1 in the stromal cells. PD-1 protein was expressed in 70% of cases, either in the tumor or stroma. The cell lines showed different PD-L1 expression at both the mRNA level and membranous protein level, and could be stimulated by IFNγ treatment. Although PD-1 gene expression could be upregulated upon IFNγ treatment among three CM cell lines, the protein level on cell membrane was low and was not upregulated following IFNγ stimulation.

Conclusions : The PD-L1/ PD-1 pathway is activated in many cases of CM and these results support the need to evaluate anti-PD-L1/ PD-1 therapy in CM patients.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×